DE602004027141D1 - Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien - Google Patents

Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien

Info

Publication number
DE602004027141D1
DE602004027141D1 DE602004027141T DE602004027141T DE602004027141D1 DE 602004027141 D1 DE602004027141 D1 DE 602004027141D1 DE 602004027141 T DE602004027141 T DE 602004027141T DE 602004027141 T DE602004027141 T DE 602004027141T DE 602004027141 D1 DE602004027141 D1 DE 602004027141D1
Authority
DE
Germany
Prior art keywords
poxviruses
adherences
adherent
production
cell lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004027141T
Other languages
German (de)
English (en)
Inventor
Fabienne Guehenneux
Bertrand Pain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivalis SA
Original Assignee
Vivalis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03291813A external-priority patent/EP1500699A1/en
Application filed by Vivalis SA filed Critical Vivalis SA
Publication of DE602004027141D1 publication Critical patent/DE602004027141D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602004027141T 2003-07-22 2004-07-22 Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien Expired - Lifetime DE602004027141D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03291813A EP1500699A1 (en) 2003-07-22 2003-07-22 Production of vaccinia virus with adherent or non adherent avian cell lines
FR0314389 2003-12-09
PCT/IB2004/002621 WO2005007840A1 (en) 2003-07-22 2004-07-22 Production of poxviruses with adherent or non adherent avian cell lines

Publications (1)

Publication Number Publication Date
DE602004027141D1 true DE602004027141D1 (de) 2010-06-24

Family

ID=34081825

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027141T Expired - Lifetime DE602004027141D1 (de) 2003-07-22 2004-07-22 Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien

Country Status (14)

Country Link
US (3) US7432101B2 (https=)
EP (2) EP1646715B1 (https=)
JP (2) JP4787156B2 (https=)
KR (1) KR101121971B1 (https=)
AT (1) ATE467678T1 (https=)
AU (1) AU2004257939B2 (https=)
CA (1) CA2531565C (https=)
DE (1) DE602004027141D1 (https=)
DK (1) DK1646715T3 (https=)
ES (1) ES2345820T3 (https=)
PL (1) PL1646715T3 (https=)
PT (1) PT1646715E (https=)
SI (1) SI1646715T1 (https=)
WO (1) WO2005007840A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
JP2005537793A (ja) 2002-09-05 2005-12-15 バヴァリアン・ノルディック・アクティーゼルスカブ 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
EP1646715B1 (en) * 2003-07-22 2010-05-12 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
AU2011253998B2 (en) * 2005-04-11 2014-04-24 Valneva Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
FR2898909A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Combinaison de marqueurs de cellules aviaires
WO2007135133A1 (en) * 2006-05-19 2007-11-29 Vivalis Avian cell lines derived from primordial germ cells useful for the production of substances of interest
HUE030533T2 (hu) 2006-06-20 2017-05-29 Transgene Sa Eljárás poxvírusok és poxvírus-készítmények elõállítására
EP2500417A1 (en) * 2006-08-09 2012-09-19 Vivalis Method of production of transgenic avian using embryonic stem cells
US8309347B2 (en) * 2007-03-05 2012-11-13 Terumo Bct, Inc. Cell expansion system and methods of use
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
CA2691868C (en) 2007-07-03 2016-12-20 Transgene S.A. Immortalized avian cell lines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
PL214884B1 (pl) * 2008-09-29 2013-09-30 Inst Immunologii I Terapii Doswiadczalnej Pan Test ELISA do wykrywania w surowicy bydlecej przeciwcial przeciwko antygenowi powierzchniowemu gp51 BLV
ES2539045T3 (es) 2009-01-19 2015-06-25 Innate Pharma Anticuerpos anti-KIR3D
CA2750055A1 (en) * 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
RU2011148791A (ru) 2009-05-12 2013-06-20 Трансген Са Иммортализованные линии клеток птиц и их применение
AU2011281982B2 (en) 2010-07-20 2015-12-17 Bavarian Nordic A/S Method for harvesting expression products
CA2810488C (en) 2010-09-07 2025-05-06 Technion Research & Development Foundation Limited NEW PROCESSES AND CULTURE MEDIA FOR THE CULTURE OF MULTIPOTENTED STEM CELLS
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
EP2660316A1 (en) 2012-05-02 2013-11-06 Helmholtz-Zentrum für Infektionsforschung GmbH Avian cell line and its use in production of protein
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US10077421B2 (en) 2014-04-24 2018-09-18 Terumo Bct, Inc. Measuring flow rate
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
WO2016088243A1 (ja) * 2014-12-05 2016-06-09 株式会社ニコン 判定装置、観察システム、観察方法、そのプログラム、細胞の製造方法、および細胞
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
CN110603058A (zh) 2017-05-15 2019-12-20 扬森疫苗与预防公司 含有病毒的稳定组合物
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
KR20210016446A (ko) 2018-05-30 2021-02-15 인스티튜트 포 리서치 인 바이오메드슨 내인성 활성화-유도 시티딘 탈아미노효소를 이용한 b 림프구의 조작
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2020104650A1 (en) 2018-11-23 2020-05-28 Valneva Se Food products comprising avian stem cells
MX2021006115A (es) 2019-01-17 2021-07-07 Boehringer Ingelheim Animal Health Usa Inc Medio libre de suero para produccion de vacuna aviar y usos del mismo.
US20230114464A1 (en) 2020-03-12 2023-04-13 Bavarian Nordic A/S Conditions Improving Poxvirus Stability
KR20230027070A (ko) * 2020-06-22 2023-02-27 코오롱생명과학 주식회사 부유세포를 이용한 백시니아 바이러스의 대량 생산 방법
TW202217002A (zh) 2020-07-13 2022-05-01 法商傳斯堅公司 免疫抑制之治療
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
US5989805A (en) 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
ATE271122T1 (de) 1996-11-12 2004-07-15 Pfizer Attenuierter lebender neospora impfstoff
EP1481409B1 (en) * 2002-02-19 2005-12-07 Cellergy Ltd Electrochemical capacitor and method for its preparation
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
CN1726276A (zh) * 2002-12-13 2006-01-25 艾文蒂斯·帕斯图尔公司 Alvac在禽胚胎干细胞上的生产
EP1646715B1 (en) * 2003-07-22 2010-05-12 Vivalis Production of poxviruses with adherent or non adherent avian cell lines
EP1528101A1 (en) * 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production

Also Published As

Publication number Publication date
AU2004257939A1 (en) 2005-01-27
AU2004257939B2 (en) 2008-06-05
JP2006527995A (ja) 2006-12-14
KR101121971B1 (ko) 2012-03-09
SI1646715T1 (sl) 2010-09-30
JP2011224009A (ja) 2011-11-10
EP1646715B1 (en) 2010-05-12
US20090239286A1 (en) 2009-09-24
US7432101B2 (en) 2008-10-07
JP4787156B2 (ja) 2011-10-05
WO2005007840A1 (en) 2005-01-27
US20100111999A1 (en) 2010-05-06
KR20060057577A (ko) 2006-05-26
DK1646715T3 (da) 2010-08-16
ATE467678T1 (de) 2010-05-15
EP1646715A1 (en) 2006-04-19
PL1646715T3 (pl) 2010-10-29
PT1646715E (pt) 2010-08-09
HK1091229A1 (en) 2007-01-12
JP5416169B2 (ja) 2014-02-12
US20060233834A1 (en) 2006-10-19
CA2531565A1 (en) 2005-01-27
CA2531565C (en) 2014-02-11
ES2345820T3 (es) 2010-10-04
EP2143788A1 (en) 2010-01-13
US7771980B2 (en) 2010-08-10

Similar Documents

Publication Publication Date Title
DE602004027141D1 (de) Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien
Lee et al. Growth kinetic models for microalgae cultivation: A review
ATE393212T2 (de) Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
DK1483369T3 (da) Fuglecellelinier til fremstiling af stoffer af interesse
MY157524A (en) Culturing embryonic stem cells, embryonic stem-like cells, or induced pluripotent stem cells with a muc1 or muc1* ligand
NO20054124L (no) Dyre-fri celle kultur metode
DK1685243T3 (da) Immortaliserede fuglecellelinjer til virusproduktion
WO2010147395A3 (en) Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same
ATE447010T2 (de) Verfahren zur produktion von viralen antigenen im grossmassstab
WO2006029198A3 (en) Culturing human embryonic stem cells
DE602004017709D1 (de) Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
ATE468390T1 (de) System und verfahren zur produktion von antikörpern in der pflanzenzellkultur
ECSP22051779A (es) Métodos para mejorar el cultivo celular con proteínas específicas de cada especie o específicas de cada género y las aplicaciones de los mismos
WO2009009797A3 (en) High fidelity restriction endonucleases
EA202091354A1 (ru) Способ культивирования клеток
MX382790B (es) Papaya con nuevos rasgos y metodos para producir tales plantas de papaya
ATE553210T1 (de) Verfahren zur herstellung von l-threonin unter verwendung eines mikroorganismus mit inaktivierten galr gen.
DE60319599D1 (de) Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle eine neurodegenerative krankheit
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
MX2022000002A (es) Método para cultivo de células adherentes en un biorreactor multiparalelo.
EA201690232A1 (ru) Генетически стабильный онколитический рнк вирус, способ его производства и применения
EP4086994A4 (en) MEMBRANE-ELECTRODE ASSEMBLY, METHOD FOR MANUFACTURING SAME, AND FUEL CELL COMPRISING SAME
BRPI0914805B8 (pt) método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição
BR112018010867A2 (pt) modelo de infecção de vírus, método de preparação do mesmo e utilização do mesmo
EP3783099C0 (en) METHOD FOR ISOLATION AND CULTURE OF NEURAL STEM CELLS WITH HIGH EFFICIENCY

Legal Events

Date Code Title Description
8364 No opposition during term of opposition